O
Ocugen, Inc. (OCGN)
NCM – Real Time Price. Currency in USD
1.38
+0.01 (1.09%)
Market open: Aug 12, 2026, 11:32 AM EDT
1.37
0.00 (0.00%)
Previous after-hours: Aug 11, 2026, 7:59 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
1.38
+0.01 (1.09%)
Market open: Aug 12, 2026, 11:32 AM EDT
1.37
0.00 (0.00%)
Previous after-hours: Aug 11, 2026, 7:59 PM EDT
Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients’ health. The company’s pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is involved in the development of OCU200, a novel recombinant fusion protein for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.
| Name | Position |
|---|---|
| Dr. Arun Upadhyay Ph.D. | Chief Scientific Officer and Head of Research & Development |
| Dr. Durgaprasad Annavajjula Ph.D. | VP, Head of Program Management & Chief of Staff |
| Dr. Shankar Musunuri M.B.A., Ph.D. | Co-Founder, CEO & Chairman |
| Dr. Vijay Tammara Ph.D. | Chief Development Officer |
| John Kouch J.D. | General Counsel |
| Mr. Abhi Gupta M.B.A. | Executive Vice President of Commercial and Business Development |
| Mr. Paul Staid | Executive Vice President of Operations |
| Ms. Jyothy Pillai M.S. | VP & Head of Regulatory & Quality |
| Ms. Kristen Craft | Head of People & Culture |
| Ms. Rita Johnson-Greene M.B.A. | CFO & Principal Accounting Officer |
| Date | Type | Document |
|---|---|---|
| 2026-08-06 | 8-K | tm2622368d1_8k.htm |
| 2026-07-30 | DEF 14A | ny20077846x2_def14a.htm |
| 2026-07-20 | PRE 14A | ny20077846x1_pre14a.htm |
| 2026-07-13 | 8-K | tm2620295d1_8k.htm |
| 2026-06-11 | 8-K | tm2617722d1_8k.htm |
| 2026-06-03 | 8-K | tm2616839d1_8k.htm |
| 2026-05-14 | 8-K | tm2614578d1_8k.htm |
| 2026-05-08 | 10-Q | ocgn-20260331.htm |
| 2026-05-07 | 8-K | tm2613898d1_8k.htm |
| 2026-05-05 | 8-K | tm2613584d1_8k.htm |